FDA Grants Fast Track Designation for CLR 131 in LPL/WM
The FDA granted fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom ’s macroglobulinemia in patients having received 2 prior treatment regimens or more.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
More News: Cancer & Oncology | Grants | Lymphoma | Macroglobulinemia | Waldenstrom's Macroglobulinemia